At a Glance
Taiwan Resonant Waves Research Corp.(TRWR) was founded in 2010 in the capital of Taiwan – Taipei. Integrating innovative bioelectronic technology with medical devices, we are dedicated to helping patients with chronic diseases better manage health-related challenges.
There is unlimited promise in the application of bioelectronic medicine in the treatment of chronic diseases. Designed and developed by TRWR, Microcurrent Electrical Nerve Stimulation technology (MENS) is currently being used as a non-invasive, physical approach to treating and alleviating symptoms associated with diabetes mellitus.
Our vision is to lead the world in groundbreaking research and development in electroceutical technology as a means of enhancing quality of life, without the adverse side effects of conventional approaches.
We are committed to addressing the unmet medical needs of those suffering from chronic diseases by pursuing advancements in bioelectronic technology and delivering cost-effective healthcare solutions.
Our vision is to establish global presence as a Taiwanese brand through strategic collaborations and partnerships around the world. We strive to continually advance our core competences in Diabetes-MENS technology and expand our patent portfolio.
2011 – 2020
Innovation is no happenstance; it is the product of courage, perseverance, opportunity, and responsibility.
From Johannes Kepler to Sir Isaac Newton, the path to innovation is one that is filled with delight, toil, glory, and blessing.
May New Chairman: Dr. Huang
March Participated in RESI Conference, Vienna, Europe 2019
June Participated in RESI Conference, Philadelphia 2019
October Start up the development project of new Transcutaneous Electrical Nerve Stimulator which is to improve blood glucose control in patients with type 2 diabetes
June 4th 2018 Participated in RESI Conference, Boston Summer 2018; In this Conference, TRWR won the First Prize of RESI Boston 2018 Innovation Challenge.
April National Taiwan University Hospital and National Cheng Kung University Hospital, in collaboration with two other medical facilities, has begun a prospective, double-blind, randomized, placebo-controlled trial of Transcutaneous Electrical Nerve Stimulator (DW1330) to improve blood glucose control in patients with type 2 diabetes
May Fast Track for Clinical Trial Program has been approved by the Department of Industrial Technology of the Ministry of Economic Affairs (MOEA)
January Developed the medical device DW1330 for the relief of type 2 diabetes
March In collaboration with the Taiwan Food and Drug Administration (TFDA) for assistance with medical device development
April Submitted a clinical trial application to TFDA for the registration of medical devices; the clinical trial at National Taiwan University Hospital (NTUH) is currently under review
August Received review approval from Institutional Review Board of NTUH of new medical device clinical trial proposal: “Prospective, double-blind, randomized, placebo-controlled trial of Transcutaneous Electrical Nerve Stimulator (DW1330) to improve blood glucose control in patients with type 2 diabetes”
June Established Academia Industry Alliance with National Chiao Tung University Department of Biological Science and Technology